Vivani Medical Q2 FY26 net loss narrows 9.86% to $6.4 million
VANI•Cash flow and trial update
- Cash used in operating activities increased to USD 12.2 million for the six months ended June 30, 2026, while cash from financing climbed to USD 15.5 million.
- First patient dosed in the SLIM-1 NPM-139 semaglutide implant trial on July 29, 2026; topline data expected in November 2026.
Quarterly results and expenses
- Vivani Medical posted a net loss of USD 6.4 million for the quarter ended June 30, 2026, narrowing from USD 7.1 million.
- Research and development expense fell 6% to USD 4.5 million on lower clinical-trial and Biopharm Division development costs.
- General and administrative expense dropped 11% to USD 2.4 million due to lower professional services in Neurostimulation and Biopharm.
- Other income rose to USD 0.5 million from USD 0.3 million, helped by derecognition of a Neurostimulation contract liability.
Related News
Boqii Holding reports awareness of unusual trading activity in Class A ordinary shares on NYSE American on Aug. 12, 2026
BQ•
Dynamix Corp. III Q2 net income rises to $1.08 million; six-month net income climbs to $2.29 million
DNMX•
